Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial

MELBOURNE, Australia, Dec. 5, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, has successfully completed its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers (DFU). Key...

2024-12-05 11:59 1521

LBB Specialties and Clariant Partner to Distribute High-Quality Pharmaceutical Grade PEGs for Ophthalmic Applications

NORWALK, Conn., Dec. 5, 2024 /PRNewswire/ -- LBB Specialties (LBBS), a leader in specialty chemicals and ingredient distribution in North America, announced a strategic partnership with Clariant, a global leader in specialty chemical manufacturing. Through this collaboration, LBB Specialties will ...

2024-12-05 04:02 1331

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved mapping and dual energy ablation catheter

AUSTIN, Texas, Dec. 4, 2024 /PRNewswire/ -- Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first in the nation to use an all-in-one high-density mapping and dual energy ablation catheter for the treatment of persistent atria...

2024-12-04 10:07 1494

Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy

* Patients in the low-dose cohort who have completed 36 weeks of treatment, 9 out of 11 (81.8%) achieved overall clinical remission and 10 out of 11 (91%) achieved immunological complete remission. * In the high dose cohort, 6 out of 7 (85.7%) patients achieved overall clinical remission and ...

2024-12-04 09:10 2090

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

SAN FRANCISCO, U.S. and SUZHOU, China, Dec. 4, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoi...

2024-12-04 08:00 2111

AC Health makes critical HIV care more accessible to Filipinos with USAID support

MANILA, Philippines, Dec. 3, 2024 /PRNewswire/ -- Ayala Healthcare Holdings, Inc. (AC Health), in partnership with the U.S. Agency for International Development (USAID), is leading the private sector's efforts to fight the HIV epidemic inthe Philippines by improving access to stigma-free care and...

2024-12-03 16:11 4546

AC Health makes critical HIV care more accessible to Filipinos with USAID support

Pfizer Receives Authorization from Health Authority for Its 20-valent Pneumococcal Conjugate Vaccine for Infants and Children

* In Hong Kong, the 20-valent Pneumococcal Conjugate Vaccine (PCV20) that offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine – helping to fight against 20 serotypesleading to most of the invasive pneumococcal diseases and pneumonia[i],[ii] – is now approved fo...

2024-12-03 15:08 1814

Fosun's Rural Doctors Program Recognized in UNGC's "20 Cases of Private Sector's Sustainable Development in China for 20 Years" Report

HONG KONG, Dec. 3, 2024 /PRNewswire/ -- This year marks the 20th anniversary of the United Nations Global Compact ("UNGC")'s introduction of Environmental, Social, and Governance (ESG) concept and principles. On29 November 2024, the UNGC held a launch event for the "20 Cases of Private Sector's S...

2024-12-03 11:47 1694

European Wellness Biomedical Group, Headed by Prof. Mike Chan, Releases New Study on Bioregenerative Blueprint for Athletic Longevity

KOTA KINABALU, Malaysia, Dec. 2, 2024 /PRNewswire/ -- European Wellness Biomedical Group (EWBG), a global leader in regenerative medicine, has unveiled a groundbreaking study led by renowned expert Prof.Mike Chan on the physiological challenges aging athletes face. The analysis explores how age ...

2024-12-02 16:30 2409

European Wellness Biomedical Group, Headed by Prof. Mike Chan, Releases New Study on Bioregenerative Blueprint for Athletic Longevity

Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Hong Kong

SHANGHAI, Dec. 2, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that Department of Health of the Gover...

2024-12-02 07:40 1636

CBC Group Completes Strategic Acquisition of UCB's Mature Product Portfolio in China

* CBC Group and Mubadala acquire UCB's mature neurology and allergy business inChina for US$680 million. * New company is named NeuroGen Pharma, led by an experienced management team with a strong track record in the biopharma industry. * Strategic acquisition under CBC's buyout strategy exp...

2024-11-30 09:00 5541

Lanchi Ventures Leads $42M Series A Financing for Allink Biotherapeutics to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. BEIJING, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage biotechnology company pioneering next-generation bispecific...

2024-11-28 21:30 3062

First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients

MELBOURNE, Australia, Nov. 28, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and Grand Pharmaceutical Group Limited (00512.HK, Grand Pharma) today announce that a first patient has been dosed in the Phase III ZIRCON-CP trial of TLX250-CDx positron ...

2024-11-28 17:22 2051

New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List

ROCKVILLE, Md. and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that the new indication...

2024-11-28 16:59 2077

Everest Medicines Announces NEFECON®, the World's First Approved Treatment for IgA Nephropathy, is Included in China's National Reimbursement Drug List

SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that NEFECON® has been included in the...

2024-11-28 13:43 1773

Antengene Announces XPOVIO®'s New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to DLBCL Patients in the Country

SHANGHAI and HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hema...

2024-11-28 13:04 1878

Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China's National Reimbursement Drug List

SAN FRANCISCO and SUZHOU, China, Nov. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...

2024-11-28 12:07 2169

Everest Medicines to Hold Investor Calls on Data Results from EVER001 Phase 1b/2a Clinical Study in Primary Membranous Nephropathy

SHANGHAI, Nov. 27, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will hold investor calls on t...

2024-11-27 19:08 2674

Kelun-Biotech's TROP2 ADC Sacituzumab tirumotecan (sac-TMT) Approved For Marketing By NMPA Of China For 2L+ Advanced or Metastatic TNBC

CHENGDU, China, Nov. 27, 2024 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization inChina from National Medical Products Administration (NMPA) for the first domestically developed trophoblast cell-surface an...

2024-11-27 14:34 1992

QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology

SINGAPORE, Nov. 26, 2024 /PRNewswire/ -- QDX proudly announces that the team led by its co-founder, Associate ProfessorGiuseppe Barca, has been honoured with the 2024 ACM Gordon Bell Prize, often referred to as the "Nobel Prize of high-performance computing." This accolade recognizes their ground...

2024-11-26 18:49 8648

1 2 345 6 7 ... 189